A prospective, randomized clinical trial of emergency treatment of chemotherapy‐induced neutropenia and febrile neutropenia by pegylated recombinant human granulocyte colony‐stimulating factor (PEG‐rhG‐CSF)

This study supported that the PEG-rhG-CSF was more effective and convenient than rhG-CSF for treating grades 3-4 neutropenia and FN in patients with breast cancer and had manageable toxicity.